Hyphens Pharma (SGX:1J5) subsidiary Hyphens Pharma entered into a marketing and distribution agreement with medac Gesellschaft für klinische Spezialpräparate for the exclusive rights to register and commercialize Metoject(r) in Singapore, Malaysia, the Philippines, and Vietnam.
Metoject(r) is a subcutaneous autoinjector pen used for the treatment of rheumatoid arthritis, according to a filing with the Singapore Exchange on Tuesday.
The pen is already commercialized in over 15 states in Europe, the US and Japan.
Shares of Hyphens Pharma were up nearly 2% in recent trading.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.